The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Chemotherapy-Induced Nausea and Vomiting

Common but preventable treatment side effect managed with risk-stratified antiemetic regimens.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Chemotherapy-Induced Nausea and Vomiting?

Chemotherapy-induced nausea and vomiting (CINV) remains a major adverse effect of cancer treatment. CINV phases include acute (within 24 hours), delayed (24-120 hours), anticipatory (before treatment due to conditioning), breakthrough (despite prophylaxis), and refractory (recurrent despite optimal therapy). Modern antiemetic strategies have reduced severe CINV substantially but suboptimal control still affects 30-40% of patients.

Pathophysiology involves multiple receptors and pathways: serotonin (5-HT3), substance P (NK1), dopamine, histamine, acetylcholine, and cannabinoid receptors, with involvement of the chemoreceptor trigger zone, vagal afferents, and higher cortical centers. Risk depends on emetogenic potential of the regimen (highly, moderately, low, minimally) and patient factors.

Guidelines (NCCN, ASCO, MASCC) recommend risk-adapted prophylaxis: triple or quadruple therapy for highly emetogenic chemotherapy (e.g., cisplatin, AC), dual or triple therapy for moderately emetogenic, and single agent for low risk. Olanzapine has been added to standard regimens. Anticipatory CINV requires behavioral interventions plus benzodiazepines.

Symptoms

Acute nausea and vomiting in first 24 hours after chemotherapy
Delayed nausea and vomiting 24-120 hours after
Anticipatory nausea before scheduled chemotherapy
Breakthrough symptoms despite prophylaxis
Anorexia and reduced oral intake
Dehydration with dry mouth, decreased urine
Electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia)
Weight loss
Fatigue and weakness
Mucositis worsening with vomiting
Hematemesis (Mallory-Weiss) in severe cases
Aspiration risk in altered mental status
Treatment delay or dose reduction
Quality of life decline

Risk Factors

Highly emetogenic chemotherapy (cisplatin, cyclophosphamide-doxorubicin)
Moderately emetogenic agents (carboplatin, oxaliplatin)
Female sex
Age younger than 50
History of motion sickness
Pregnancy-induced emesis history
Prior CINV in earlier cycles
Anxiety and depression
Low alcohol intake
Concurrent radiation therapy
Comorbid GI disorders

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Vomiting more than 4 episodes in 24 hours
  • Inability to keep liquids down for more than 24 hours
  • Signs of dehydration (dizziness, decreased urination)
  • Weight loss greater than 5 lbs in a week
  • Signs of electrolyte imbalance (muscle cramps, palpitations)
  • Hematemesis or coffee-ground vomiting
  • Severe abdominal pain with vomiting
  • Vomiting interfering with medication intake
  • Anticipatory nausea before treatment
  • Mood symptoms worsening with CINV

Treatment Methods

01
Stratify chemotherapy emetogenicity (highly, moderately, low, minimal)
02
Highly emetogenic (HEC): NK1 antagonist + 5-HT3 antagonist + dexamethasone + olanzapine
03
Moderately emetogenic (MEC): 5-HT3 antagonist + dexamethasone (with or without NK1 or olanzapine)
04
Low emetogenic: dexamethasone or 5-HT3 antagonist or metoclopramide
05
Minimal emetogenic: prophylaxis not routinely indicated
06
5-HT3 antagonists: ondansetron, granisetron, palonosetron
07
NK1 antagonists: aprepitant, fosaprepitant, netupitant, rolapitant
08
Dexamethasone short course (typically days 1-4)
09
Olanzapine 5-10 mg days 1-4 added to standard regimens
10
Breakthrough CINV: add agent from different class (prochlorperazine, metoclopramide, haloperidol, lorazepam, olanzapine, cannabinoids)
11
Anticipatory CINV: behavioral therapy, hypnosis, lorazepam evening before and morning of treatment
12
Hydration: oral or IV fluids, replace electrolytes
13
Small frequent meals, bland foods, avoid strong odors
14
Ginger and acupressure (P6 wristbands) as adjuncts
15
Cannabinoids (dronabinol, nabilone) for refractory cases
16
Monitor for serotonin syndrome with multiple serotonergic agents
17
Reassess regimen each cycle and adjust based on response
18
Patient education on prophylaxis adherence and breakthrough plan
19
Consider chemotherapy modification if refractory severe CINV
20
Multidisciplinary collaboration (oncology, pharmacy, palliative)

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.